EUVIMEDEUVIMED entdecken
Open Access

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Jaleh Fallah iD, Jianjin Xu iD, Chana Weinstock, Xin Gao iD, Brian L Heiss iD, William F Maguire iD, Elaine Chang iD, Sundeep Agrawal, Shenghui Tang iD, Laleh Amiri-Kordestani iD, Richard Pazdur iD, Paul G Kluetz und 1 weitere

Journal of Clinical Oncology · 10.05.2024 · 42 (14) · 1687-1698

DOI: 10.1200/jco.23.02105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2024. Verfasst von Jaleh Fallah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors, Recombinational DNA Repair, Mutation. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We performed a pooled analysis of multiple trials of poly(ADP-ribose) polymerase inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) to investigate the efficacy of PARPi in each individual homologous recombination repair (HRR) mutated (m) gene. PATIENTS AND METHODS We pooled patient-level data from trials of PARPi in mCRPC that reported mutation status in individual HRR genes. Any HRR gene with available data across all the randomized trials of PARPi in first-line mCRPC was selected. The hazard ratios (HRs; 95% CI) for radiographic progression-free survival (rPFS; by blinded independent review) and overall survival (OS) of a PARPi plus an androgen receptor pathway inhibitor (ARPI) relative to placebo plus an ARPI in the pool of three randomized trials in first-line mCRPC were calculated using Kaplan-Meier estimates and a Cox proportional hazards model. RESULTS In ATMm (N = 268), rPFS HR was 1.05 (0.74 to 1.49) and OS HR was 1.18 (0.82 to 1.71). In BRCA1m (N = 64), rPFS HR was 0.51 (0.23 to 1.1) and OS HR was 0.74 (0.34 to 1.61). In BRCA2m (N = 422), rPFS HR was 0.31 (0.23 to 0.42) and OS HR was 0.66 (0.49 to 0.89). In CDK12m (N = 164), rPFS HR was 0.50 (0.32 to 0.80) and OS HR was 0.63 (0.39 to 0.99). In CHEK2m (N = 172), rPFS HR was 1.06 (0.67 to 1.66) and OS HR was 1.53 (0.95 to 2.46). In PALB2m (N = 41) rPFS HR was 0.52 (0.23 to 1.17) and OS HR was 0.78 (0.34 to 1.8). CONCLUSION In this pooled analysis, benefit from PARPi appeared greatest for patients with BRCA1m, BRCA2m, CDK12m, and PALB2m. Given limitations of this exploratory analysis, the apparent lack of benefit from PARPi in patients with CHEK2m or ATMm should be further explored in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairMutationRandomized Controlled Trials as TopicBRCA2 ProteinHumansMaleBRCA1 ProteinUnited StatesCheckpoint Kinase 2Cyclin-Dependent KinasesAtaxia Telangiectasia Mutated ProteinsFanconi Anemia Complementation Group N ProteinProgression-Free SurvivalAndrogen Receptor AntagonistsAgedReceptors, AndrogenAntineoplastic Combined Chemotherapy Protocols

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsCDK12 protein, humanBRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanCHEK2 protein, humanCheckpoint Kinase 2BRCA1 protein, humanCyclin-Dependent KinasesAtaxia Telangiectasia Mutated Proteins

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.
  • Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD.

ORCID-Profile: Jaleh Fallah, Jianjin Xu, Xin Gao, Brian L Heiss, William F Maguire, Elaine Chang, Shenghui Tang, Laleh Amiri-Kordestani, Richard Pazdur

Zitieren

APA

Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., Pazdur, R., Kluetz, P. G., & Suzman, D. L. (2024). Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. Journal of Clinical Oncology, 42(14), 1687-1698. https://doi.org/10.1200/jco.23.02105

Vancouver

Fallah J, Xu J, Weinstock C, Gao X, Heiss BL, Maguire WF, et al. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. Journal of Clinical Oncology. 2024;42(14):1687-1698. doi:10.1200/jco.23.02105

BibTeX
@article{Fallah2024,
  author = {Fallah, Jaleh and Xu, Jianjin and Weinstock, Chana and Gao, Xin and Heiss, Brian L and Maguire, William F and Chang, Elaine and Agrawal, Sundeep and Tang, Shenghui and Amiri-Kordestani, Laleh and Pazdur, Richard and Kluetz, Paul G and Suzman, Daniel L},
  title = {Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {14},
  pages = {1687--1698},
  doi = {10.1200/jco.23.02105}
}
Kostenlos starten →